Actively Recruiting
Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Atrioventricular Block With Preserved Ejection Fraction
Led by Samsung Medical Center · Updated on 2026-03-11
200
Participants Needed
4
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Conventional right ventricular pacing (RVP) has been associated with ventricular dyssynchrony and an increased risk of pacing-induced cardiomyopathy, which may lead to worse clinical outcomes. These adverse effects are more pronounced in patients with pre-existing left ventricular dysfunction. To overcome these limitations, left bundle branch area pacing (LBBAP), which directly engages the cardiac conduction system to preserve physiological ventricular activation, has been increasingly adopted in clinical practice. However, in patients with atrioventricular block and preserved left ventricular ejection fraction (LVEF ≥50%), evidence demonstrating the long-term clinical superiority of LBBAP over conventional RVP remains limited. As a result, both pacing strategies continue to be used in current practice. This multicenter randomized trial aims to compare the efficacy, safety, and lead stability of LBBAP using a stylet-driven extendable screw-in lead versus conventional RVP in patients with atrioventricular block and preserved ejection fraction.
CONDITIONS
Official Title
Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Atrioventricular Block With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients requiring permanent pacemaker implantation due to third-degree atrioventricular block
- Patients with first- or second-degree atrioventricular block expecting a ventricular pacing burden of 40% or more
- Patients with atrial fibrillation and slow ventricular response expecting a ventricular pacing burden of 40% or more
You will not qualify if you...
- Prior implantation of a cardiac pacemaker or implantable cardioverter-defibrillator
- Left ventricular ejection fraction 50% or lower
- Indication for cardiac resynchronization therapy
- Life expectancy of 1 year or less, including patients not eligible for heart transplantation due to end-stage heart failure, those with do-not-resuscitate orders, patients receiving hospice care after refusal of life-sustaining treatment, or patients with terminal cancer not eligible for chemotherapy or radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea
Actively Recruiting
2
Samsung Medical Center
Seoul, Seoul, South Korea, 06351
Actively Recruiting
3
Samsung Changwon Hospital
Changwon, South Korea
Actively Recruiting
4
Veterans Health Service Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
S
Seung-Jung Park, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here